BiotechTube

bezuclastinib

Phase 2Recruiting
0 watching 0 views this week⚡ Active
49
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Advanced Systemic Mastocytosis (AdvSM)

Conditions

Advanced Systemic Mastocytosis (AdvSM), SM With an Associated Hematologic Neoplasm (SM-AHN), Mast Cell Leukemia (MCL), Aggressive Systemic Mastocytosis (ASM)

Trial Timeline

Nov 9, 2021 → Jul 1, 2026

NCT ID
NCT04996875

About bezuclastinib

bezuclastinib is a phase 2 stage product being developed by Cogent Biosciences for Advanced Systemic Mastocytosis (AdvSM). The current trial status is recruiting. This product is registered under clinical trial identifier NCT04996875. Target conditions include Advanced Systemic Mastocytosis (AdvSM), SM With an Associated Hematologic Neoplasm (SM-AHN), Mast Cell Leukemia (MCL).

Hype Score Breakdown

Clinical
17
Activity
12
Company
7
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT06915766Pre-clinicalActive
NCT04996875Phase 2Recruiting

Competing Products

20 competing products in Advanced Systemic Mastocytosis (AdvSM)

See all competitors
ProductCompanyStageHype Score
AK-105AkesoPhase 1
32
AFM24 + Atezolizumab 840 MG in 14 ML InjectionAffimedPhase 1/2
33
EXS21546BiotrialPhase 1/2
33
SY-1365 (Part 1) + Carboplatin + Fulvestrant + SY-1365 (Cohort 2) + SY-1365 (Cohort 5) + SY-1365 (Part 2 Single Agent)Syros PharmaceuticalsPhase 1
25
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
52
Pemetrexed + Erlotinib + Pemetrexed + ErlotinibEli LillyPhase 2
52
NBTXR3NanobiotixPhase 1/2
36
pegfilgrastim + LY2523355Eli LillyPhase 1
33
SON-1010Sonnet BioTherapeuticsPhase 1
28
SON-1010Sonnet BioTherapeuticsPhase 1/2
36
BT1718Bicycle TherapeuticsPhase 1/2
33
Zentalis + GemzarZentalis PharmaceuticalsPhase 2
44
IMC-18F1Eli LillyPhase 1
33
Tadalafil + GemcitabineEli LillyPhase 1
33
OKI-179OnKure TherapeuticsPhase 1
25
OKI-219 + Fulvestrant + Trastuzumab + Tucatinib + Atirmociclib + RibociclibOnKure TherapeuticsPhase 1
25
LY3499446 + Abemaciclib + Cetuximab + Erlotinib + DocetaxelEli LillyPhase 1/2
41
LY3434172Eli LillyPhase 1
33
ACR-2316Acrivon TherapeuticsPhase 1
25
BBP-398LianBioPhase 1
25

Other Products from Cogent Biosciences

CGT9486 plus sunitinib + CGT9486 + Sunitinib + Sunitinib + Midazolam + CGT9486 plus sunitinibPhase 3
74
Bezuclastinib in combination with sunitinibPhase 2
49
Bezuclastinib Tablets (Formulation A) + Bezuclastinib Tablets (Formulation B) + Placebo TabletsPhase 2
49
CGT4859Phase 1/2
38
CGT9486 + Pexidartinib + SunitinibPhase 1/2
38